ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Immutep Ltd

Immutep Ltd (IMMP)

1.90
-0.04
(-2.06%)
Closed July 22 4:00PM
1.89
-0.01
(-0.53%)
After Hours: 7:56PM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
1.89
Bid
1.88
Ask
1.92
Volume
262,998
1.87 Day's Range 1.95
0.00 52 Week Range 0.00
Market Cap
Previous Close
1.94
Open
1.91
Last Trade
10
@
1.905
Last Trade Time
Financial Volume
$ 503,200
VWAP
1.9133
Average Volume (3m)
-
Shares Outstanding
1,187,306,209
Dividend Yield
-
PE Ratio
-9.23
Earnings Per Share (EPS)
-0.03
Revenue
-
Net Profit
-39.9M

About Immutep Ltd

Immutep Ltd. is a clinical stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesse... Immutep Ltd. is a clinical stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3's unique ability to stimulate or suppress the immune response. Immutep's lead clinical candidate, eftilagimod alpha ('efti'), is a soluble LAG-3 protein and first-in-class MHC Class II agonist that stimulates both innate and adaptive immunity to fight cancer. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
Headquarters
Sydney, New South Wales, Aus
Founded
1970
Immutep Ltd is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker IMMP. The last closing price for Immutep was $1.94. Over the last year, Immutep shares have traded in a share price range of $ 0.00 to $ 0.00.

Immutep currently has 1,187,306,209 shares outstanding. The market capitalization of Immutep is $2.30 billion. Immutep has a price to earnings ratio (PE ratio) of -9.23.

IMMP Latest News

Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer

Media Release Final discussion with the FDA, successfully concluding the regulatory preparations for the TACTI-004 Phase III trial design to evaluate efti in combination with KEYTRUDA®...

Immutep Receives Regulatory Clearance for Phase I Study of First-in-Class LAG-3 Agonist Antibody Designed to Treat Autoimmune Diseases

Media Release Study expected to enrol first participants during Q3 CY2024 SYDNEY, AUSTRALIA, July 17, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the...

Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression

Media Release Efti in combination with KEYTRUDA® (pembrolizumab) achieved a 35.5% response rate in evaluable patients (N=31), according to RECIST 1.1, among the highest recorded for a treatment...

Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results

Company to Host Webcast on 12th July at 9am AEST (7pm ET, 11 July) SYDNEY, AUSTRALIA, July 03, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a...

Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer

Media Release SYDNEY, AUSTRALIA, June 25, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel...

Immutep successfully completes institutional placement and institutional component of entitlement offer

Sydney, Australia, June 05, 2024 (GLOBE NEWSWIRE) -- Immutep Limited ACN 009 237 889 (ASX: IMM, NASDAQ: IMMP) (Immutep or the Company) is pleased to announce the successful completion of its...

Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial

Phase III collaboration will evaluate efti in combination with KEYTRUDA, MSD’s anti-PD-1 therapy, and standard chemotherapy in first-line non-small cell lung cancer (1L NSCLC)TACTI-004 Phase III...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MIRAMIRA Pharmaceuticals Inc
$ 5.01
(627.35%)
151.42M
CMAXCareMax Inc
$ 5.7101
(261.40%)
100.56M
NUKKNukkleus Inc
$ 0.5415
(69.22%)
24.87M
SNOASonoma Pharmaceuticals Inc
$ 0.423
(37.34%)
4.57M
LPSNLivePerson Inc
$ 1.2999
(31.30%)
8.57M
CGBSCrown LNG Holdings Ltd
$ 0.9902
(-29.77%)
3.29M
LGCBLinkage Global Inc
$ 3.7833
(-27.45%)
166.7k
SPECSpectaire Holdings Inc
$ 0.395
(-24.76%)
1.78M
GSUNGolden Sun Health Technology Group Ltd
$ 5.07
(-24.55%)
155.37k
SLNASelina Hospitality PLC
$ 0.0364
(-23.04%)
75.77M
NVDANVIDIA Corporation
$ 123.54
(4.76%)
239M
SQQQProShares UltraPro Short QQQ
$ 8.09
(-4.37%)
183.65M
MIRAMIRA Pharmaceuticals Inc
$ 5.01
(627.35%)
158.14M
SERVServe Robotics Inc
$ 8.73
(15.63%)
151.56M
NCPLNetcapital Inc
$ 0.1118
(7.50%)
124.37M

IMMP Discussion

View Posts
Monksdream Monksdream 2 days ago
IMMP under $2
👍️0
Vector2112 Vector2112 1 week ago
Refinitiv Logo
As of 06/27/2024

SellUnderperformHoldOutperformSelected Value:Buy
Refinitiv Stock Reports Plus
Refinitiv maintains a current price target of $8.64 for IMMP.
👍️0
glenn1919 glenn1919 1 week ago
IMMP......................https://stockcharts.com/h-sc/ui?s=IMMP&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 2 weeks ago
IMMP under $2
👍️0
Monksdream Monksdream 3 months ago
IMMP under $3
👍️0
Monksdream Monksdream 10 months ago
IMMP under $2
👍️0
The Night Stalker The Night Stalker 1 year ago
nice
👍️0
The Night Stalker The Night Stalker 1 year ago
nice
👍️0
The Night Stalker The Night Stalker 1 year ago
nice
👍️0
The Night Stalker The Night Stalker 1 year ago
strong
👍️0
The Night Stalker The Night Stalker 1 year ago
nice
👍️0
The Night Stalker The Night Stalker 1 year ago
ready
👍️0
The Night Stalker The Night Stalker 1 year ago
nice
👍️0
The Night Stalker The Night Stalker 1 year ago
strong
👍️0
The Night Stalker The Night Stalker 1 year ago
watching
👍️0
The Night Stalker The Night Stalker 1 year ago
watching
👍️0
The Night Stalker The Night Stalker 1 year ago
dip
👍️0
The Night Stalker The Night Stalker 1 year ago
dip
👍️0
The Night Stalker The Night Stalker 1 year ago
nice
👍️0
The Night Stalker The Night Stalker 1 year ago
im in my bio DRMA, one at a time


RIGL rip for more
👍️0
The Night Stalker The Night Stalker 1 year ago
beast
👍️0
DewDiligence DewDiligence 1 year ago
IMMP +65% on interim (single-arm) phase-2 data for LAG-3 drug with Keytruda in NSCLC:

https://finance.yahoo.com/news/immutep-efti-combination-pembrolizumab-achieves-120000596.html

IMMP’s eftilagimod alpha is a LAG-3 protein that targets the same biologic pathway as BMY’s relatlimab, one of the component drugs (along with Opdivo) in Opdulag.

BMY’s Opdulag, which was FDA approved in Mar 2022 for first-line melanoma, is already selling at an annualized rate of $500M in the US alone (#msg-171784010).

Please see #msg-168259768 for related info.
👍️0
Invest-in-America Invest-in-America 1 year ago
IMMP: Very likely the hands-down WINNER of this Wall Street day, Peeps!!! (Just when ya thought that CANCER was no longer TRENDING.)

👍️0
stocks2watch stocks2watch 2 years ago
Going to move up
👍️0
make it happen make it happen 3 years ago
It's cool covered most average was $3.68
👍️0
calahan67 calahan67 3 years ago
I think you're not taking into account whats in the pipeline mainly several studies involving much larger pharmaceutical interested the immune boosting properties of eftaligamod. Imo this company and ceo are the real deal. Forget the outlays and remember its research and development that costs the most up front no matter what pharm you're talking about
👍️0
make it happen make it happen 3 years ago
More debt than revenue, large negatives on everything (cash flow, returns and profit margins.

Profitability
Profit Margin 0.00%
Operating Margin (ttm) -300.79%

Management Effectiveness
Return on Assets (ttm) -20.00%
Return on Equity (ttm) -61.68%

Income Statement
Revenue (ttm) 6.35M
Revenue Per Share (ttm) 0.14
Quarterly Revenue Growth (yoy) -76.90%
Gross Profit (ttm) -6.66M
EBITDA -17.07M
Net Income Avi to Common (ttm) -27.36M
Diluted EPS (ttm) -0.4500

Total Debt (mrq) 9.75M
Book Value Per Share (mrq) 0.94

Cash Flow Statement
Operating Cash Flow (ttm) -14.67M
Levered Free Cash Flow (ttm) -7.67M
👍️0
sgunderbarth sgunderbarth 3 years ago
IMMP Interesting action....
👍️0
ClayTrader ClayTrader 3 years ago
* * $IMMP Video Chart 04-08-2021 * *

Link to Video - click here to watch the technical chart video

👍️0
make it happen make it happen 3 years ago
Any positives in the numbers? Decent news but will need to raise money to keep anything going imho

IMMP is "ELIGIBLE" to receive development based milestones and sales based royalties. They do not have sales and drug is not out.


Profitability
Profit Margin 0.00%
Operating Margin (ttm) -300.79%

Management Effectiveness
Return on Assets (ttm) -20.00%
Return on Equity (ttm) -61.68%

Income Statement
Revenue (ttm) 4.85M
Revenue Per Share (ttm) 0.11
Quarterly Revenue Growth (yoy) -76.90%
Gross Profit (ttm) -6.66M
EBITDA -13.03M
Net Income Avi to Common (ttm) -20.89M
Diluted EPS (ttm) -0.4600

Balance Sheet
Total Cash Per Share (mrq) 0.65 will blow through it and need a serious capital raise imho
Total Debt (mrq) 7.45M
Book Value Per Share (mrq) 0.71

Cash Flow Statement
Operating Cash Flow (ttm) -11.2M
Levered Free Cash Flow (ttm) -5.86M
👍️0
make it happen make it happen 3 years ago
Had R/S a couple years ago and was $0.53 about a year ago
👍️0
make it happen make it happen 3 years ago
Quarterly growth -76.9%, returns are negative, zero profit and cash flow is very negative.

Profitability
Profit Margin 0.00%
Operating Margin (ttm) -300.79%

Management Effectiveness
Return on Assets (ttm) -20.00%
Return on Equity (ttm) -61.68%

Income Statement
Revenue (ttm) 4.85M
Revenue Per Share (ttm) 0.11
Quarterly Revenue Growth (yoy) -76.90%
Gross Profit (ttm) -6.66M
EBITDA -13.03M
Net Income Avi to Common (ttm) -20.89M
Diluted EPS (ttm) -0.4600

Balance Sheet
Total Cash Per Share (mrq) 0.65
Total Debt (mrq) 7.45M
Book Value Per Share (mrq) 0.71

Cash Flow Statement
Operating Cash Flow (ttm) -11.2M
Levered Free Cash Flow (ttm) -5.86M
👍️0
make it happen make it happen 3 years ago
I agree it states that Novartis is in chagre and IMMP is "ELIGIBLE" to receive milestones and payments. Previous reverse split. IMHO prob going to be bled
👍️0
reverse_long reverse_long 3 years ago
IMMP never holds any spikes. Every time it has fastrack or patent news it dumps away. It is the real deal to dump very hard. GLTA!
👍️0
calahan67 calahan67 3 years ago
This is the real deal folks
👍️0
ClayTrader ClayTrader 3 years ago
* * $IMMP Video Chart 03-25-2021 * *

Link to Video - click here to watch the technical chart video

👍️0
DewDiligence DewDiligence 3 years ago
IMMP up on BMY's LAG-3 coattails: #msg-162784750.
👍️0
calahan67 calahan67 3 years ago
And they have a very sharp ceo if you've seen any of their videos he tells it straight up imo
👍️0
calahan67 calahan67 3 years ago
Up huge on no news a great big sleeper imo
👍️0
calahan67 calahan67 3 years ago
Looks like accumulation is beginning a slow churn higher
👍️0
everything everything 4 years ago
Interesting company, looks to be in reversal but dip opportunity may be in the works.
👍️0
akamaii akamaii 4 years ago
Like it here
👍️0
lecorb lecorb 4 years ago
$IMMP: TIPRANKS, SCORE, UPGRADE TO 10 OUTPERFORM! ANALIST RATINGS: PT: $6.50 MODERATE BUY! LOW: @5.50, MED:@6.50, HI: $8.00 Jason McCarthy Maxim Group 5 Stars target $8.00 ranking Buy analystAction Reiterated date 6 days ago Last calification.
👍️0